Cidara Therapeutics (CDTX) Gains as Analyst Highlights Related to Drug Resistant Fungi

January 29, 2021 9:46 AM EST
Get Alerts CDTX Hot Sheet
Price: $2.13 +1.91%

Rating Summary:
    14 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cidara Therapeutics (NASDAQ: CDTX), others highlighted at Maxim the battle against drug-resistant fungi and bacteria.

"This was highlighted in a 1/27 New York Times (NYT) article that discusses the increased spread of drug-resistant pathogens in the setting of COVID-19. There have been isolated outbreaks of these pathogens in several states, including California, where in Los Angeles there are now ~250 cases of the highly drug resistant yeast (fungus) Candida auris," the analyst notes.

In addition to CDTX, the anlayst highlighted Appili Therapeutics (APTI:CN), Matinas Biopharma (NASDAQ: MTNB), Scynexis (NASDAQ: SCYX) and TFF Pharmaceuticals (NASDAQ: TFFP).

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Trader Talk